GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AddLife AB (OSTO:ALIF B) » Definitions » 3-Year EBITDA Growth Rate

AddLife AB (OSTO:ALIF B) 3-Year EBITDA Growth Rate : 14.30% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is AddLife AB 3-Year EBITDA Growth Rate?

AddLife AB's EBITDA per Share for the three months ended in Mar. 2024 was kr1.53.

During the past 12 months, AddLife AB's average EBITDA Per Share Growth Rate was -13.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 14.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 39.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 30.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of AddLife AB was 66.80% per year. The lowest was 10.10% per year. And the median was 24.40% per year.


Competitive Comparison of AddLife AB's 3-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, AddLife AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AddLife AB's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where AddLife AB's 3-Year EBITDA Growth Rate falls into.



AddLife AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


AddLife AB  (OSTO:ALIF B) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


AddLife AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of AddLife AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


AddLife AB (OSTO:ALIF B) Business Description

Traded in Other Exchanges
Address
Brunkebergstorg 5, Box 3145, Stockholm, SWE, 103 62
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in Labtech and Medtech segments. The Labtech segment, which accounts for the majority of the company revenue, provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service. The Medtech segment includes products related to surgery, thoracic medicine, neurology, wound care, anesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare. AddLife mainly caters to hospitals & laboratories within healthcare, research, colleges, and universities, as well as the food and pharmaceutical industries. Its geographical segments are Sweden, Denmark, Finland, Norway, and Other countries.

AddLife AB (OSTO:ALIF B) Headlines

No Headlines